In the case of CTCL, six (22.22%) patients underwent therapy for comorbidities, primarily for hypertension, with one (3.70%) patient receiving angiotensin-converting enzyme inhibitors and two (7.41%) receiving beta-blockers. Here, ACE is linked to hypertensive disorder.